|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0034866,
umls-concept:C0087111,
umls-concept:C0205225,
umls-concept:C0205373,
umls-concept:C0441833,
umls-concept:C0600558,
umls-concept:C1512888,
umls-concept:C1519814,
umls-concept:C1524063,
umls-concept:C1999270
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-4-19
|
|
pubmed:abstractText |
Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BlohmerJens-UweJU,
pubmed-author:EiermannWolfgangW,
pubmed-author:GoldhirschAronA,
pubmed-author:HortobagyiGabriel NGN,
pubmed-author:JackeszRaimundR,
pubmed-author:JonatWalterW,
pubmed-author:KaufmannManfredM,
pubmed-author:LebeauAnnetteA,
pubmed-author:LoiblSibylleS,
pubmed-author:MakrisAndreasA,
pubmed-author:MillerWilliamW,
pubmed-author:SchollSuzyS,
pubmed-author:SeeberSigfriedS,
pubmed-author:SemiglazovVladimirV,
pubmed-author:SmitsRonR,
pubmed-author:SouchonRainerR,
pubmed-author:StearnsVeredV,
pubmed-author:UntchMichaelM,
pubmed-author:ValagussaPinucciaP,
pubmed-author:von MinckwitzGunterG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1940-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16622270-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16622270-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16622270-Breast Neoplasms,
pubmed-meshheading:16622270-Disease-Free Survival,
pubmed-meshheading:16622270-Female,
pubmed-meshheading:16622270-Humans,
pubmed-meshheading:16622270-Neoadjuvant Therapy,
pubmed-meshheading:16622270-Patient Selection,
pubmed-meshheading:16622270-Prognosis,
pubmed-meshheading:16622270-Randomized Controlled Trials as Topic,
pubmed-meshheading:16622270-Receptors, Estrogen,
pubmed-meshheading:16622270-Receptors, Progesterone
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, J.W. Goethe-University Hospital, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
|
|
pubmed:publicationType |
Journal Article,
Practice Guideline
|
